Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Forxiga | Harvard | Heart | Heart Attack | Heart Failure | Hemorrhagic Stroke | Internal Medicine | Invokana | Ischemic Stroke | Jardiance | Medicare | Metformin | Sodium | Stroke | Study | Women